Statins in the Prevention of Contrast-Induced Nephropathy

  • Anthony C. Chyou
  • Anay Thodge
  • Dmitriy N. Feldman
  • Rajesh V. SwaminathanEmail author
Coronary Artery Disease (D Feldman and V Voudris, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Coronary Artery Disease

Opinion statement

Coronary angiography and percutaneous coronary interventions are common procedures that utilize iodinated contrast medium to visualize the coronary arterial tree and treat stable and unstable ischemic heart syndromes. Exposure to contrast agents can cause acute and persistent worsening of renal function leading to increased morbidity and mortality. Certain patient characteristics such as age, presence of diabetes, congestive heart failure, chronic kidney disease, hemodynamic instability on presentation, and type and volume of contrast used can increase the risk of developing contrast-induced nephropathy (CIN) and its subsequent complications. Despite the lack of a universal definition, CIN is typically defined as an increase in serum creatinine ≥0.5 mg/dL or 25 % above baseline 48 to 72 h after contrast exposure. Previous research has shown the benefits of adequate intravenous hydration with iso-osmolar crystalloids and the importance of limiting the amount of low-osmolar and iso-osmolar contrast used to prevent the development of CIN. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have anti-inflammatory and anti-apoptotic properties with few side effects, making it an attractive therapeutic option for prevention of CIN. A number of trials have examined the benefit of different types of statins, high-dose versus low-dose statins, loading versus chronic dosing of statins, in various clinical presentations including acute coronary syndromes and elective procedures, and in those with associated comorbidities such as anemia and chronic kidney disease. In this review, we will summarize recent data regarding statin therapy for prevention of contrast-induced nephropathy.


Contrast-induced nephropathy Prevention Statins 



This investigation was supported by grant UL1TR000457 of the Clinical and Translational Science Center at Weill Cornell Medical College.

Compliance with Ethics Guidelines

Conflict of Interest

Dr. Anthony C. Chyou, Dr. Anay Thodge, and Dr. Rajesh V. Swaminathan each declare no potential conflicts of interest.

Dr. Dmitriy N. Feldman is a section editor for Current Treatment Options in Cardiovascular Medicine.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008;51:1419–28.CrossRefPubMedGoogle Scholar
  2. 2.
    Weisbord SD, Palevsky PM. Contrast-induced acute kidney injury: short and long-term implications. Semin Nephrol. 2011;31:300–9.CrossRefPubMedCentralPubMedGoogle Scholar
  3. 3.
    Alpert MA. Do statins reduce the risk of contrast-induced acute kidney injury in patients undergoing coronary angiography or percutaneous coronary interventions? J Am Coll Cardiol. 2014;63:80–2.CrossRefPubMedGoogle Scholar
  4. 4.
    Li Y, Liu Y, Fu L, Mei C, Dai B. Efficacy of short-term high-dose statin in preventing contrast-induced nephropathy: a meta-analysis of seven randomized controlled trials. PLoS One. 2012;7:e34450.CrossRefPubMedCentralPubMedGoogle Scholar
  5. 5.
    Bartholomew BA, Harjai KJ, Dukkipati S, Boura JA, Yerkey MW, Glazier S, et al. Impact of nephropathy after percutaneous intervention and a method for risk stratification. Am J Cardiol. 2004;93:1515–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Subramanian S, Tumlin J, Bapat B, et al. Economic burden of contrast-induced nephropathy: implications for prevention strategies. J Med Econ. 2007;10:119–34.CrossRefPubMedGoogle Scholar
  7. 7.
    Pappy R, Stavrakis S, Hennebry TA, Abu-Fadel MS. Effect of statin therapy on contrast-induced nephropathy after coronary angiography: a meta-analysis. Int J Cardiol. 2011;151:348–53.CrossRefPubMedGoogle Scholar
  8. 8.
    Patti G, Ricottini E, Nusca A, Colonna G, Pasceri V, D’Ambrosio A, et al. Short-term, high-dose atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty-contrast-induced nephropathy] trial.). Am J Cardiol. 2011;108:1–7.CrossRefPubMedGoogle Scholar
  9. 9.••
    Han Y, Zhu G, Han L, Hou F, Huang W, Liu H, et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J Am Coll Cardiol. 2014;63:62–70. This study demonstrated that short-term low-dose rosuvastatin significantly reduced risk of CIN in patients with diabetes and stage 2 CKD undergoing coronary or peripheral angiography/interventions as compared to placebo.CrossRefPubMedGoogle Scholar
  10. 10.•
    Leoncini M, Toso A, Maioli M, Tropeano F, Villani S, Bellandi F. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: results from the PRATO-ACS study (protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome). J Am Coll Cardiol. 2014;63:71–9. The PRATO-ACS study showed that in statin-naïve patients presenting in ACS undergoing coronary angiography/intervention, a short course of high-dose rosuvastastin decreased the incidence of CIN and lower rate of death or nonfatal myocardial infarction at 6 month.CrossRefPubMedGoogle Scholar
  11. 11.
    Stacul F, Adam A, Becker CR, Davidson C, Lameire N, McCullough PA, et al. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol. 2006;98:59K–77.CrossRefPubMedGoogle Scholar
  12. 12.
    Pannu N, Wiebe N, Tonelli M. Prophylaxis strategies for contrast-induced nephropathy. JAMA. 2006;295:2765–79.CrossRefPubMedGoogle Scholar
  13. 13.
    Tumlin J, Stacul F, Adam A, Becker CR, Davidson C, Lameire N, et al. Pathophysiology of contrast-induced nephropathy. Am J Cardiol. 2006;98:14K–20.CrossRefPubMedGoogle Scholar
  14. 14.
    Calvin AD, Misra S, Pflueger A. Contrast-induced acute kidney injury and diabetic nephropathy. Nat Rev Nephrol. 2010;6:679–88.CrossRefPubMedGoogle Scholar
  15. 15.
    Seeliger E, Sendeski M, Rihal CS, Persson PB. Contrast-induced kidney injury: mechanisms, risk factors, and prevention. Eur Heart J. 2012;33:2007–15.CrossRefPubMedGoogle Scholar
  16. 16.
    Khraibi AA, Knox FG. Effect of renal decapsulation on renal interstitial hydrostatic pressure and natriuresis. Am J Physiol. 1989;257:R44–8.PubMedGoogle Scholar
  17. 17.
    Lecian D, Demova H, Lodererova A, Zdychova J, Kluckova H, Teplan V, et al. Renal effects of HMG-CoA reductase inhibition in a rat model of chronic inhibition of nitric oxide synthesis. Kidney Blood Press Res. 2006;29:135–43.CrossRefPubMedGoogle Scholar
  18. 18.
    Toth PP. An update on the benefits and risks of rosuvastatin therapy. Postgrad Med. 2014;126:7–17.CrossRefPubMedGoogle Scholar
  19. 19.
    DiNicolantonio JJ, Lavie CJ, Serebruany VL, O’Keefe JH. Statin wars: the heavyweight match–atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease. Postgrad Med. 2013;125:7–16.CrossRefPubMedGoogle Scholar
  20. 20.
    Schacter M. Chemical, pharmacokinetic and pharmacodynamics properties of statins: an update. Fundam Clin Pharmacol. 2005;19:117–25.CrossRefGoogle Scholar
  21. 21.
    Luvai A, Mbagaya W, Hall AS, Barth JH. Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease. Clin Med Insights Cardiol. 2012;6:17–33.PubMedCentralPubMedGoogle Scholar
  22. 22.
    Agarwal R. Statin induced proteinuria: renal injury or renoprotection? J Am Soc Nephrol. 2004;15:2502–3.CrossRefPubMedGoogle Scholar
  23. 23.
    Quintavalle C, Flore D, De Micco F, Visconti G, Focaccio A, Golla B, et al. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation. 2012;126:3008–16.CrossRefPubMedGoogle Scholar
  24. 24.
    Al-Otaibi KE, Al Elaiwi AM, Tariq M, Al-Asmari AK. Simvastatin attenuates contrast-induced nephropathy through modulation of oxidative stress, proinflammatory myeloperoxidase, and nitric oxide. Oxid Med Cell Longev. 2012;2012:831748.CrossRefPubMedCentralPubMedGoogle Scholar
  25. 25.
    Kwok CS, Pang CL, Yeong JK, Loke YK. Measures to treat contrast-induced nephropathy: overview of reviews. Br J Radiol. 2013;86:20120272.CrossRefPubMedCentralPubMedGoogle Scholar
  26. 26.••
    Gandhi S, Mosleh W, Abdel-Qadir H, Farkouh ME. Statins and contrast-induced acute kidney injury with coronary angiography. Am J Med. 2014;127:987–1000. The largest and most updated meta-analysis of 15 randomized controlled trials showed that short-term statin exposure reduced the risk of CIN as compared to placebo and persisted in the group presenting in acute coronary syndromes with high-dose group but not in the low-dose group. Subgroup analyses also conferred benefit in patients with diabetes, chronic kidney disease, congestive heart failure, and those receiving >140 mL of contrast medium.CrossRefPubMedGoogle Scholar
  27. 27.••
    Liu Y, Liu YH, Tan N, Chen JY, Zhou YL, Li LW, et al. Comparision of the efficacy of rosuvastatin versus atorvastatin in preventing contrast induced nephropathy in patients with chronic kidney disease undergoing percutaneous coronary intervention. PLoS One. 2014;9:e111124. The first head-to-head trial comparing short-term pretreatment with rosuvastatin 10 mg to atorvastatin 20 mg in statin-naïve patients with CKD undergoing elective PCI and demonstrated similar efficacies in preventing CIN and longer term of all-cause mortality and major adverse cardiovascular events.CrossRefPubMedCentralPubMedGoogle Scholar
  28. 28.
    Piorkowski M, Fischer S, Stellbaum C, Jaster M, Martus P, Morguet AJ, et al. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets? J Am Coll Cardiol. 2007;49:1035–42.CrossRefPubMedGoogle Scholar
  29. 29.
    Xie H, Ye Y, Shan G, Zhang S, Fang Q, Yang D, et al. Effect of statins in preventing contrast-induced nephropathy: an updated meta-analysis. Coron Artery Dis. 2014;25(7):565–74.CrossRefPubMedGoogle Scholar
  30. 30.
    Xinwei J, Xianghua F, Jing Z, Xinshun G, Ling X, Weize F, et al. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol. 2009;104:519–24.CrossRefPubMedGoogle Scholar
  31. 31.
    Barbieri L, Verdoia M, Schaffer A, Nardin M, Marino P, De Luca G. The role of statins in the prevention of contrast induced nephropathy: a meta-analysis of 8 randomized trials. J Thromb Thrombolysis. 2014;38:493–502.CrossRefPubMedGoogle Scholar
  32. 32.
    Zhang BC, Li WM, Xu YW. High-dose statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis. Can J Cardiol. 2011;27:851–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Li W, Fu X, Wang Y, Li X, Yang Z, Wang X, et al. Beneficial effects of high-dose atorvastatin pretreatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention. Cardiology. 2012;122:195–202.CrossRefPubMedGoogle Scholar
  34. 34.
    Jo S-H, Hahn J-Y, Lee SY, Kim HJ, Song YB, Choi JH, Choi SH, Lee SH, Gwon HC. High Dose Atorvastatin Pretreatment for Preventing Contrast-Induced Nephropathy in Patients Receiving Primary Percutaneous Coronary Intervention. J Cardiovasc Med. 2014. E-published ahead of print.Google Scholar
  35. 35.
    Ozhan H, Erden I, Ordu S, Aydin M, Caglar O, Basar C, et al. Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Angiology. 2010;61:711–4.CrossRefPubMedGoogle Scholar
  36. 36.
    McClellan W, Aronoff SL, Bolton WK, Hood S, Lorber DL, Tang KL, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004;20:1501–10.CrossRefPubMedGoogle Scholar
  37. 37.
    Brookhart MA, Solomon DH, Glynn RJ, Ridker PM. Effect of rosuvastatin on hemoglobin levels in patients with anemia and low-grade inflammation: a post hoc analysis of the JUPITER trial. J Clin Pharmacol. 2011;51:1483–7.CrossRefPubMedGoogle Scholar
  38. 38.
    Persson PB, Patzak A. Renal haemodynamic alterations in contrast medium-induced nephropathy and the benefit of hydration. Nephrol Dial Transplant. 2005;20 Suppl 1:2–5.CrossRefGoogle Scholar
  39. 39.
    Kim SJ, Salem MR, Joseph NJ, Madayag MA, Cavallino RP, Crystal GJ. Contrast media adversely affect oxyhemoglobin dissociation. Anesth Analg. 1990;71:73–6.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Anthony C. Chyou
    • 1
  • Anay Thodge
    • 2
  • Dmitriy N. Feldman
    • 1
    • 3
  • Rajesh V. Swaminathan
    • 1
    • 3
    Email author
  1. 1.Greenberg Division of CardiologyWeill Cornell Medical College, New York-Presbyterian HospitalNew YorkUSA
  2. 2.Wayne State University School of MedicineDetroitUSA
  3. 3.Cardiac Catheterization LaboratoriesWeill Cornell Medical CollegeNew YorkUSA

Personalised recommendations